ADC Therapeutics’ (ADCT) Outperform Rating Reiterated at Royal Bank of Canada
Royal Bank of Canada restated their outperform rating on shares of ADC Therapeutics (NYSE:ADCT – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock. ADCT has been the subject of several other reports. Stephens raised their price target on shares of […]
Royal Bank of Canada restated their outperform rating on shares of ADC Therapeutics (NYSE:ADCT – Free Report) in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock. ADCT has been the subject of several other reports. Stephens raised their price target on shares of […]
